Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper

Pier Luigi Zinzani, Paolo Corradini, Alessandro M. Gianni, Massimo Federico, Armando Santoro, Umberto Vitolo, Giovanni Barosi, Sante Tura

Research output: Contribution to journalArticlepeer-review


Brentuximab vedotin (BV) is approved for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and relapsed or refractory systemic anaplastic large-cell lymphoma. Several uncertainties remain regarding the optimal use of the drug in its approved indications as well as outside them. This article reports recommendations on the use of BV issued during a consensus project, sponsored by the Italian Society of Hematology (SIE) and its affiliate societies, Società Italiana di Ematologia Sperimentale (SIES) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Scientific evidence on BV was evaluated by a panel of experts, and consensus was developed by group discussion for key questions selected according to the clinical relevance. The following key issues were addressed: testing CD30 positivity to assess eligibility to BV; assessing practice indications of BV in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma; providing pretreatment evaluation of patients candidates to BV; monitoring the response to BV; managing patients treated with BV; and assessing the role of BV in other CD30-positive lymphomas.

Original languageEnglish
Article number620
Pages (from-to)507-513
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number9
Publication statusPublished - Sept 1 2015


  • Brentuximab vedotin
  • Consensus project
  • Guidelines
  • Hodgkin lymphoma
  • Systemic anaplastic large-cell lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper'. Together they form a unique fingerprint.

Cite this